News

News Subscription

Nov 13. 2023 / Ad hoc announcement
Basilea announces acquisition of fosmanogepix, a phase-3-ready broad-spectrum antifungal
Read more
Download
Oct 31. 2023 / Ad hoc announcement
Basilea announces exclusive license and option agreement for potential first-in-class clinical-stage antibacterial agent
Read more
Download
Oct 19. 2023 / Ad hoc announcement
Basilea announces acquisition of novel clinical-stage antifungal for treatment of Aspergillus mold infections
Read more
Download
Oct 17. 2023
Basilea reports new data for ceftobiprole (Zevtera®) presented at US IDWeek Congress 2023
Read more
Download
Oct 02. 2023 / Ad hoc announcement
Basilea announces FDA acceptance of New Drug Application for antibiotic ceftobiprole
Read more
Download
Sep 28. 2023
Basilea announces New England Journal of Medicine publication of phase 3 data on ceftobiprole for the treatment of Staphylococcus aureus bacteremia
Read more
Download
Aug 15. 2023 / Ad hoc announcement
Basilea reports strong revenue and profit growth in first half-year 2023
Read more
Download
Aug 04. 2023 / Ad hoc announcement
Basilea announces submission of a New Drug Application to the US Food and Drug Administration for its antibiotic ceftobiprole
Read more
Download
Jun 08. 2023 / Ad hoc announcement
Continued strong Cresemba® (isavuconazole) sales by Pfizer trigger USD 26 million sales milestone payments to Basilea
Read more
Download
Apr 26. 2023
Basilea shareholders approve all proposals of the board of directors at the annual general meeting
Read more
Download